NEOD001
AssetAlso ELT1-01, Hu2A4, Birtamimab
Monoclonal antibody targeting misfolded light chain aggregates to promote amyloid clearance
- Stage
- Phase 3
- Modality
- Antibody
- Target
- Proteostasis
- 3
- Indications
- 4
- Trials
- 1
- Developer
Indications
3Primary systemic (al) amyloidosis
Phase 3, Terminated, NCT02312206, clinicaltrials.gov, 7 Oct 2026
AL amyloidosis
Phase 2, Completed, NCT02632786, clinicaltrials.gov, 7 Oct 2026
Primary amyloidosis
Phase 1, Completed, NCT01707264, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials4
- Evidence for its targets1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.